PR Newswire
11 Jan 2023, 06:30 GMT+10
![]() |
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.
This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications; as well as occlusive disease of the superficial femoral artery (SFA); and coronary In-Stent Restenosis (ISR).
Enrollment of the SELUTION SLR coronary de novo study will begin in the US within the next few months.
This will complement the substantial experience that the company has already gained with the SELUTION DeNOVO trial in Europe (ClinicalTrials.gov Identifier: NCT04859985). More than 800 patients of the 3,326 planned have been enrolled in this ground-breaking coronary randomized controlled study comparing SELUTION SLR vs. any limus drug-eluting stent (DES). The study is powered to demonstrate superiority of SELUTION SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease. This is the largest DEB study ever initiated and has the potential to change medical practice where implants (metal stents) have been the standard of care for more than 30 years.
"Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularization of coronary artery disease. The SELUTION SLR coronary de novo study is the first of its kind in the USA and will provide important data on the efficacy and safety of sirolimus- eluting balloon as a viable alternative to drug-eluting stent, leaving nothing behind post-PCI and eliminating in-stent restenosis and related complications," said Dr. Ron Waksman, Professor of Cardiology at Georgetown University, Director of Cardiovascular Research at MedStar Heart and Vascular Institute, Washington DC and Chairman of the MedAlliance Coronary Study Steering Committee.
"Coronary de novo lesions are the largest potential opportunity for use of DEB's: the data has shown clearly that DES don't work well in small vessels, long, or bifurcated lesions or in patients with diabetes or risk of high bleeding complications. These patients represent 60% of all patients currently treated with DES, who may now benefit from this exciting new DEB technology," added Jeffrey B. Jump, Chairman and CEO of MedAlliance.
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
MedAlliance's unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days.
SELUTION SLR 014 PTCA is commercially available in Europe, Asia, the Middle East and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 coronary units have already been used for patient treatment in routine clinical practice or as part of clinical trials.
About MedAlliance
MedAlliance is a medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland, MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information visit: www.medalliance.com
Get a daily dose of Sydney Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Sydney Sun.
More InformationBENGALURU, India: A major regulatory breakthrough in India could mark a turning point for Starlink, Elon Musk's satellite internet...
NEW YORK, New York - Renewed fears about inflation, and U.S. Donald Trump's trade policies say American markets take a deep dive Friday....
NEW YORK CITY, New York: Segway is recalling about 220,000 scooters in the U.S. because of a safety issue that can cause riders to...
BEIJING, China: As global tech firms navigate rising geopolitical tensions, China has extended a warm signal to Apple, one of its most...
NEW YORK, New York - Shares in automakers fell sharply Thursday after U.S.President Donald Trump imposed a 25 percent tariff on all...
WASHINGTON, D.C.: Federal safety regulators have launched a new investigation into Ford's best-selling F-150 pickup trucks after receiving...
The death toll in Friday's massive earthquake in Myanmar has risen to nearly 700, and is expected to rise significantly. At least another...
WASHINGTON, D.C.: In response to soaring egg prices and supply shortages driven by a devastating bird flu outbreak, the United States...
WASHINGTON, D.C.: U.S. President Donald Trump vowed this week that more countries will be added to the Abraham Accords, the series...
TOKYO, Japan: This week, Japan's cherry blossom season officially began as experts confirmed the first blooms in Tokyo. A specialist...
CAPE TOWN, South Africa: The U.S. Embassy in South Africa said it received a list of over 67,000 people interested in refugee status...
RALEIGH, North Carolina: North Carolina's highest court has ruled that a mother and her teenage son can pursue a lawsuit over a COVID-19...